603880.SHG Jiangsu Nanfang Medical
- Market cap
- CNY 2.31B
- P/E
- -
- P/B
- 15.53x
- ROE
- -26.1%
- Dividend yield
- 1.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603880.SHG undervalued?
Graham numberThe Graham number of Jiangsu Nanfang Medical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Nanfang Medical fundamental analysis
No fundamental analysis for Jiangsu Nanfang Medical yet.
Jiangsu Nanfang Medical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Nanfang Medical
Jiangsu Nanfang Medical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of transdermal products, medical adhesive tapes and bandages, sports protective equipment, first aid kits, nitrile gloves, and protective equipment in China and internationally. The company offers medical proof fabrics, care products, band-aids, and applications; medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, …
Full company profileJiangsu Nanfang Medical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Nanfang Medical annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 444M | 489M | 480M | 492M | 1.07B | 527M | 545M | 600M | 603M | 601M | 543M |
| Gross Profit | 128M | 127M | 107M | 103M | 350M | 94.5M | 67.6M | 33.8M | -28.9M | 23.4M | 52.8M |
| Operating Income | 60.5M | 49.7M | 45.3M | 25.4M | 102M | -28.1M | -29.4M | -147M | -198M | -59.9M | -26.2M |
| EBITDA | 80.8M | 68.6M | 62.6M | 47.5M | 138M | 10.2M | 32.6M | -71.1M | -124M | -26.2M | -15.3M |
| Net Income | 52.0M | 47.6M | 39.3M | 28.1M | 98.1M | -22.8M | -14.6M | -147M | -191M | -102M | -38.7M |
| EPS | 0.24 | 0.20 | 0.14 | 0.10 | 0.34 | -0.08 | -0.05 | -0.51 | -0.65 | -0.35 | -0.13 |
| Balance Sheet | |||||||||||
| Total Assets | 517M | 823M | 846M | 870M | 1.07B | 1.24B | 1.46B | 1.28B | 1.06B | 928M | 847M |
| Total Liabilities | 260M | 285M | 286M | 302M | 372M | 580M | 836M | 803M | 772M | 747M | 697M |
| Shareholders' Equity | 253M | 532M | 557M | 564M | 697M | 650M | 617M | 469M | 279M | 177M | 148M |
| Cash & Short-term Investments | 97.8M | 268M | 238M | 234M | 325M | 173M | 149M | 118M | 72.5M | 25.9M | 19.5M |
| Total Debt | 153M | 156M | 156M | 142M | 178M | 354M | 474M | 452M | 473M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 99.4M | 49.2M | 52.7M | 33.0M | 154M | -84.3M | 31.3M | 15.5M | 63.3M | 47.7M | - |
| Capital Expenditure | 54.0M | 31.1M | 77.8M | 56.4M | 123M | 212M | 146M | 66.2M | 32.4M | 13.2M | 14.2M |
| Free Cash Flow | 45.3M | 18.1M | -25.0M | -23.4M | 30.8M | -296M | -115M | -50.7M | 30.9M | 34.5M | 29.8M |
| Ratios | |||||||||||
| ROE | 20.5% | 9.0% | 7.1% | 5.0% | 14.1% | -3.5% | -2.4% | -31.4% | -68.3% | -57.4% | -26.1% |
| ROA | 10.1% | 5.8% | 4.6% | 3.2% | 9.1% | -1.8% | -1.0% | -11.5% | -18.0% | -11.0% | -4.6% |
| Net Profit Margin | 11.7% | 9.7% | 8.2% | 5.7% | 9.1% | -4.3% | -2.7% | -24.6% | -31.6% | -16.9% | -7.1% |
| Debt to Equity | 0.60x | 0.29x | 0.28x | 0.25x | 0.25x | 0.54x | 0.77x | 0.96x | 1.69x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Nanfang Medical dividends
- Dividend yield
- 1.12%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 21, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 25.9M | 0.09 | - |
| 2024 | CNY 27.1M | 0.09 | - |
| 2023 | CNY 21.6M | 0.07 | - |
| 2022 | CNY 18.6M | 0.06 | - |
| 2021 | CNY 33.8M | 0.12 | - |
| 2020 | CNY 8.45M | 0.03 | 8.6% |
| 2019 | CNY 20.8M | 0.07 | 74.1% |
| 2018 | CNY 21.5M | 0.07 | 54.7% |
| 2017 | CNY 46.6M | 0.20 | 97.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 21, 2021.
Who owns Jiangsu Nanfang Medical
- Insiders 53.02%
- Institutions 3.08%
- Public & others 43.90%
- Shares outstanding 289M
- Free float 131M
Jiangsu Nanfang Medical company profile
- Company name
- Jiangsu Nanfang Medical
- Ticker
- 603880.SHG
- ISIN
- CNE100002WH0
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 789
- Fiscal year end
- December
- Address
- No. 1, Guoxiang Road, Changzhou, China, 213149
- Phone
- 86 519 8636 2360
- Website
- nfmedical.com.cn
About Jiangsu Nanfang Medical
Jiangsu Nanfang Medical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of transdermal products, medical adhesive tapes and bandages, sports protective equipment, first aid kits, nitrile gloves, and protective equipment in China and internationally. The company offers medical proof fabrics, care products, band-aids, and applications; medical wound dressings, capsicum plasters, physical therapy tapes, pain relief sleeves, rigid sports tapes, wound plaster dressings, medical eye pads, elastic stretch tapes, corn removal plasters, waterproof adhesive tapes, pain relief patches, kinesiology tapes, surgical tapes, zinc oxide adhesives, masks, and nitrile gloves; and customized products. It also provides medical devices, disinfectant products, personal protective equipment, and high-performance membrane materials. In addition, the company engages in equity investment and business management consulting activities. Jiangsu Nanfang Medical Co., Ltd. was founded in 1990 and is headquartered in Changzhou, China.
Jiangsu Nanfang Medical management
3- Mr. Lingfeng HeChairman of the Board, GM & Acting Financial Officer · born 1986
- Ms. Linye XuDeputy GM & Board Secretary · born 1991
- Yahua WangAccounting Supervisor